EKG in athletes

this issue of NEJM has an article on role of cardiac screening pre-sports participation (see athlete screening preparticipation nejm 2013 in dropbox, or DOI: 10.1056/NEJMclde1311642. article presents differing views on the appropriate extent of screening, esp whether to use EKG as part of the screen, noting that:

--not common (around 100-150 young athletes die/yr in US), pales in comparison to numbers of youth who die from accidents, homicide, suicide, and even non-exercise assoc sudden death
--still obviously a very tragic event when it happens, typically unsuspected in apparently totally healthy, vigorous person
--everyone agrees to do pre-athletic screen with history/physical, best with standardized screen, assessing cardiac history of family and patient (eg  dizziness, fainting, chest pain, shortness of breath and palpitations during or after exercise, or a change in exercise tolerance).  but family history only picks up 16% and only 1/2 have antecedant symptoms prior to sudden death
--really important to focus on high school kids, since 65% of deaths in young athletes are in high school kids

so, you can read the pros and cons, but i thought i'd send along a reference from the british journal of sports medicine which has consensus criteria on the abnormal EKG in athletes (one issue with doing EKGs in these kids is the large number of false positives, leading to some unnecessary testing and unnecessary exclusion from sports) -- see athlete screening ekg br j sports med 2013 in dropbox, or doi:10.1136/bjsports-2012-092067

here is the summary table:

Table 1 Abnormal ECG findings in athletes

Abnormal ECG finding                      Definition

T-wave inversion                               >1 mm in depth in two or more leads V2–V6, II
                                                        and aVF, or I and aVL (excludes III, aVR and V1)

ST segment depression                      ≥0.5 mm in depth in two or more leads

Pathologic Q waves                            >3 mm in depth or >40 ms in duration in two or
                                                        more leads (except for III and aVR)

Complete left bundle branch block        QRS ≥120 ms, predominantly negative QRS
                                                        complex in lead V1 (QS or rS), and upright
                                                        monophasic R wave in leads I and V6

Intraventricular conduction delay          Any QRS duration ≥140 ms

Left axis deviation                             −30° to −90°

Left atrial enlargement                       Prolonged P wave duration of >120 ms in leads I
                                                        or II with negative portion of the P wave ≥1 mm in
                                                        depth and ≥40 ms in duration in lead V1
Right ventricular hypertrophy pattern    R−V1+S−V5>10.5 mm AND right axis deviation
                                                        >120°

Ventricular pre-excitation                    PR interval <120 ms with a delta wave (slurred
                                                        upstroke in the QRS complex) and wide QRS
                                                        (>120 ms)
Long QT interval*                                QTc≥470 ms (male)
                                                         QTc≥480 ms (female)
                                                         QTc≥500 ms (marked QT prolongation)
Short QT interval*                               QTc≤320 ms

Brugada-like ECG pattern                     High take-off and downsloping ST segment
                                                         elevation followed by a negative T wave in ≥2
                                                        leads in V1–V3

Profound sinus bradycardia                 <30 BPM or sinus pauses ≥ 3 s

Atrial tachyarrhythmias                         Supraventricular tachycardia, atrial-fibrillation,
                                                          atrial-flutter
Premature ventricular contractions        ≥2 PVCs per 10 s tracing

Ventricular arrhythmias                        Couplets, triplets and non-sustained ventricular
                                                          tachycardia

Note: These ECG findings are unrelated to regular training or expected
physiological adaptation to exercise, may suggest the presence of
pathological cardiovascular disease, and require further diagnostic evaluation.

*The QT interval corrected for heart rate is ideally measured with heart rates of
60–90 bpm. Consider repeating the ECG after mild aerobic activity for borderline or
abnormal QTc values with a heart rate <50 bpm.

Comments

Post a Comment

if you would like to receive the near-daily emails regularly, please email me at gmodest@uphams.org

Popular posts from this blog

HDL a negative risk factor? or cholesterol efflux??

Although the data on HDL being protective of atherosclerotic disease is pretty consistent, there are negative studies, and the data on medications which dramatically improve HDL levels (eg, the cholesteryl ester transfer protein --CETP --inhibitors, such as torcetrapib) are clinically disappointing. there have been several explanations for this. for example, some HDL particles are "pro-inflammatory" and elicit an atherosclerotic response (which may be related to apolipoprotein C-III). a new article in NEJM highlights another angle -- that the issue is not the HDL number, but HDL's functionality in the reverse transport of cholesterol, as measured by the cholesterol efflux capacity (see  lipids HDL efflux capacity vs amt NEJM 2014 in dropbox, or  DOI: 10.1056/NEJMoa1409065). This article looks at the Dallas Heart Study, where they measured HDL levels, HDL particle concentrations, and cholesterol efflux capacity in 2924 adults free of cardiovascular disease and followed p
Read more

Drug company shenanigans: narcolepsy drug

I have not done a blog for a long time on drug company shenanigans. So it is my great pleasure to bring up a brand-new drug company approach to garner huge amounts of money (see  https://www.nytimes.com/2023/02/28/business/jazz-narcolepsy-avadel-patents.html?smid=nytcore-ios-share&referringSource=articleShare  ).  Based on an article by  Rebecca Robbins of the New York Times, who has written several articles on drug company excesses   As background, this will be my 42 nd  such blog: for the array, see  https://bucommunitymed.wpengine.com/page/4/?s=drug+company+shenanigans   Th e drug company  approach  this time  to extending  their  patents has a few “interesting” angles: -- this is a medication manufactured by Jazz Pharmaceuticals to treat narcolepsy: there are 2 versions: Xyrem and Xywav (Xywav has less sodium, so is marketed to those who should be on a low sodium diet). These meds are basically derivatives of gammahydroxybutyric acid (GHB)      -- the drug actually has a pretty
Read more

UPDATE: ASCVD risk factor critique

  I decided to do an extensive update of my prior ASCVD (atherosclerotic cardiovascular disease) risk analysis and critique of risk calculators, with much more information about the “non-traditional” risk factors. I felt that there should be more data/clarification, since I think we are really undertreating/not preventing the most common cause of death by relying on the ASCVD risk calculators   -- Cardiovascular risk models:      -- many of us rely on the various cardiovascular risk models to determine the appropriate approach to patients, and these are often integrated into the electronic medical records      -- these risk models have several very important limitations:          -- they are typically based on community data, eg from the Framingham study etc. But, in clinical practice, we are dealing with the individual and not the community:              -- there is very clear evidence that there are many individual risk factors that are associated with increased risk of a cardiovascu
Read more